Volitionrx (VNRX) Cash from Investing Activities (2011 - 2025)
Volitionrx (VNRX) posted Cash from Investing Activities of -$10967.0 for Q4 2025, up 85.72% on a QoQ basis from -$76783.0 in Q2 2025, and up 94.46% year-over-year from -$5639.8 in Q4 2024.
Volitionrx (VNRX) Cash from Investing Activities (2011 - 2025) Analysis & Trends
Volitionrx's Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$10967.0 for Q4 2025.
- Quarterly Cash from Investing Activities rose 94.46% year-over-year to -$10967.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$89558.0 (up 84.39% YoY) and the FY2025 annual result came in at -$89558.0, up 84.39% from the prior year.
- Cash from Investing Activities was -$10967.0 for Q4 2025 at Volitionrx, up from -$76783.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$1808.0 in Q1 2025 and bottomed at -$578752.0 in Q4 2022.
- A 5-year average of -$225836.8 and a median of -$197859.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities slumped 1047.15% — and 2025, when it soared 97.71%.
- Volitionrx's Cash from Investing Activities stood at -$128572.0 in 2021, then tumbled by 350.14% to -$578752.0 in 2022, then surged by 46.66% to -$308722.0 in 2023, then soared by 35.91% to -$197859.0 in 2024, then jumped by 94.46% to -$10967.0 in 2025.
- Business Quant data shows VNRX's Cash from Investing Activities at -$10967.0 in Q4 2025, -$76783.0 in Q2 2025, and -$1808.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.94 Bn | 126.06 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.65 Bn | 67.19 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.32 Bn | 26.03 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.10 Bn | 21.98 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Volitionrx | 89,535.16 | -1.03 Mn | - | -10,967.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10,967.00 |
| Dec 31, 2025 | -10,967.00 |
| Jun 30, 2025 | -76,783.00 |
| Jun 30, 2025 | -76,783.00 |
| Mar 31, 2025 | -1,808.00 |
| Mar 31, 2025 | -1,808.00 |
| Dec 31, 2024 | -197,859.00 |
| Dec 31, 2024 | -197,859.00 |
| Sep 30, 2024 | -136,737.00 |
| Sep 30, 2024 | -136,737.00 |
| Jun 30, 2024 | -160,447.00 |
| Jun 30, 2024 | -160,447.00 |
| Mar 31, 2024 | -78,809.00 |
| Mar 31, 2024 | -78,809.00 |
| Dec 31, 2023 | -308,722.00 |
| Dec 31, 2023 | -308,722.00 |
| Sep 30, 2023 | -273,041.00 |
| Sep 30, 2023 | -273,041.00 |
| Jun 30, 2023 | -301,394.00 |
| Jun 30, 2023 | -301,394.00 |